CLAIMS

1. ~~A method of~~ Use of a multispecific antibody for the manufacture of a medicament for treating or managing an autoimmune disorder in ~~, the method comprising administering to~~ a patient in need of such treatment or management ~~a multispecific antibody~~, wherein the multispecific antibody binds to B-cell maturation antigen (BCMA) and an antigen that promotes activation of one or more T cells.

2. The ~~method~~ use according to claim 1, wherein the autoimmune disorder is anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE).

3. ~~A method of~~ Use of a multispecific antibody for the manufacture of a medicament for treating or managing antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)~~, the method comprising administering to~~ in a patient in need of such treatment or management ~~a multispecific antibody~~, wherein the multispecific antibody binds to BCMA and to an antigen that promotes activation of one or more T cells.

4. The ~~method~~ use according to any one of claims 1 to 3, wherein:

(a) the antigen that promotes activation of one or more T cells is selected from the group consisting of CD3, TCRα, TCRβ, TCRγ, TCRζ, ICOS, CD28, CD27, HVEM, LIGHT, CD40, 4-1BB, OX40, DR3, GITR, CD30, TIM1, SLAM, CD2, or CD226, preferably wherein the antigen that promotes activation of one or more T cells is CD3~~.~~;

~~5. The method according to any one of claims 1 to 4, wherein~~ (b) the multispecific antibody is a bispecific antibody that binds to BCMA and CD3~~.~~; and/or

~~6. The method according to any one of claims 1 to 5, wherein~~ (c) the multispecific antibody is a bispecific antibody, optionally wherein bispecific antibody is a trivalent bispecific antibody comprising two Fab fragments of an anti-BCMA antibody, one Fab

fragment of an anti-CD3 antibody, and one Fc portion, wherein the bispecific antibody is in the format BCMA Fab - Fc - CD3 Fab - BCMA Fab.

~~7~~5. The ~~method~~ use according to any one of claims 1 to ~~6~~4, wherein the multispecific antibody comprises an anti-BCMA antibody, or antigen binding fragment thereof, comprising a CDR1H, CDR2H, CDR3H CDR1L, CDR2L and CDR3L region combination selected from:

(a) CDR1H region of SEQ ID NO:21, CDR2H region of SEQ ID NO:22, CDR3H region of SEQ ID NO:17, CDR1L region of SEQ ID NO:27, CDR2L region of SEQ ID NO:28, and CDR3L region of SEQ ID NO:20;
(b) CDR1H region of SEQ ID NO:21, CDR2H region of SEQ ID NO:22, CDR3H region of SEQ ID NO:17, CDR1L region of SEQ ID NO:25, CDR2L region of SEQ ID NO:26 , and CDR3L region of SEQ ID NO:20; or
(c) CDR1H region of SEQ ID NO:15, CDR2H region of SEQ ID NO:16, CDR3H region of SEQ ID NO:17, CDR1L region of SEQ ID NO:18, CDR2L region of SEQ ID NO:19 , and CDR3L region of SEQ ID NO:20.

~~8~~6. The ~~method~~ use according to any one of claims 1 to ~~7~~5, wherein the multispecific antibody comprises:

(a) an anti-BCMA antibody, or antigen binding fragment thereof, having a variable region VH comprising an amino acid sequence that is at least 90% identical to, at least 95% identical to, at least 99% identical to, or identical to the amino acid sequence of SEQ ID NO:10 and a variable region VL comprising an amino acid sequence that is at least 90% identical to, at least 95% identical to, at least 99% identical to, or identical to the amino acid sequence of SEQ ID NO:14;
(b) an anti-BCMA antibody, or antigen binding fragment thereof, having a variable region VH comprising an amino acid sequence that is at least 90% identical to, at least 95% identical to, at least 99% identical to, or identical to the amino acid sequence of SEQ ID NO:10 and a variable region VL comprising an amino acid sequence that is at least 90% identical to, at least 95% identical to, at least 99% identical to, or identical to the amino acid sequence of SEQ ID NO:13; or

(c) an anti-BCMA antibody, or antigen binding fragment thereof, having a variable region VH comprising an amino acid sequence that is at least 90% identical to, at least 95% identical to, at least 99% identical to, or identical to the amino acid sequence of SEQ ID NO:9 and a variable region VL comprising an amino acid sequence that is at least 90% identical to, at least 95% identical to, at least 99% identical to, or identical to the amino acid sequence of SEQ ID NO:11.

~~9~~7. The ~~method~~ use according to any one of claims 1 to ~~8~~6, wherein the multispecific antibody comprises an anti-CD3 antibody, or antigen binding fragment thereof, which comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:2, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:3, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:4, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:5, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:6.

~~10~~8. The ~~method~~ use according to claim ~~9~~7, wherein ~~wherein~~ the anti-CD3 antibody or antigen binding fragment thereof comprises a variable region VH comprising an amino acid sequence that is at least 90% identical to, at least 95% identical to, at least 99% identical to, or identical to the amino acid sequence of SEQ ID NO:7 and a variable region VL comprising an amino acid sequence that is at least 90% identical to, at least 95% identical to, at least 99% identical to, or identical to the amino acid sequence of SEQ ID NO:8.

~~11~~9. The ~~method~~ use according to any one of claims 1 to 3, wherein the multispecific antibody comprises a heavy and light chain set consisting of polypeptides:

(a) SEQ ID NO:48, SEQ ID NO:55, SEQ ID NO:56, and two copies of SEQ ID NO:57;
(b) SEQ ID NO:48, SEQ ID NO:58, SEQ ID NO:59, and two copies of SEQ ID NO:60; or
(c) SEQ ID NO:48, SEQ ID NO:61, SEQ ID NO:62, and two copies of SEQ ID NO:63.

~~12~~10. The ~~method~~ use of any one of claims 1 to ~~11~~9, wherein the autoimmune disease is selected from the group consisting of Systemic lupus erythematosus, IgA nephropathy,

Membranous Nephropathy, Myasthenia gravis, Neuromyelitis optica, Pemphigus vulgaris, Anti-PAD4-activating rheumatoid arthritis, Sensitized / preformed antibodies in solid organ transplant, Guillain-Barre Syndrome (Acute inflammatory demyelinating polyneuropathy – AIDP), Chronic inflammatory demyelinating polyneuropathy (CIDP), Immune thrombocytopenic purpura, rheumatoid arthritis and ANCA-associated vasculitis (AAV).

~~13~~11. The ~~method~~ use according to any one of claims 3 to ~~12~~10, wherein the AAV comprises diseases that are selected from the group consisting of granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA), microscopic polyangiitis (MPA) and renal-limited ANCA-associated vasculitis.

~~14. The method according to claim 13, wherein the AAV is granulomatosis with polyangiitis (GPA).~~

~~15. The method according to claim 13, wherein the AAV is eosinophilic granulomatosis with polyangiitis (EGPA).~~

~~16. The method according to claim 13, wherein the AAV is microscopic polyangiitis (MPA).~~

~~17. The method of claim 13, wherein the AAV is renal-limited ANCA-associated vasculitis.~~

~~18~~12. The ~~method~~ use according to any one of claims 1 to ~~17~~11, wherein the autoimmune disorder (e.g. AAV) is refractory or relapsed~~.~~; and/or

~~19. The method according to any one of claims 1 to 18,~~ wherein the autoimmune disorder (e.g. AAV) is newly diagnosed.

~~20~~13. The ~~method~~ use according to any one of claims 3 to ~~16~~12~~, 18 or 19~~, wherein the AAV is affecting one or more body parts of the patient selected from nervous system, eyes, nose, heart, kidneys, stomach, intestine, lungs, joints, muscles and skin.

~~21~~14. The ~~method~~ use according to any one of claims 3 to ~~20~~13, wherein the AAV is generalized with presence of life- or major organ-threatening manifestations.

~~22~~15. The ~~method~~ use according to claim ~~21~~14, wherein the patient has diffuse alveolar hemorrhage (DAH).

~~23~~16. The ~~method~~ use according to any one of claims 3 to ~~20~~13, wherein the AAV is localized without organ-threatening manifestations.

~~24~~17. The ~~method of~~ use according to any one of claims 1 to ~~23~~16, wherein:
(a) the patient is in need of plasmablast reduction~~.~~;

~~25. The method according to any one of claims 1 to 24, wherein~~ (b) the patient is at risk of developing cytokine release syndrome~~.~~;

~~26. The method of any one of claims 1 to 25, wherein~~ (c) the patient is at risk of developing infection~~.~~;

~~27. The method of any one of claims 1 to 26, wherein~~ (d) the patient is in need of induction of remission~~.~~; and/or

~~28. The method of any one of claims 1 to 27, wherein~~ (e) the patient is in need of maintenance of remission.

~~29~~18. The ~~method of~~ use according to any one of claims 1 to ~~28~~17, wherein the treatment or management results in:
(a) ~~the method results in~~ a reduction of plasmablasts in the patient by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, at least 95%, or 100% relative to no treatment or a reference treatment~~.~~;

~~30. The method of any one of claims 1 to 29, wherein the method results in~~ (b) a lowered incidence of cytokine release syndrome in the patient by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, at least 95%, or 100% relative to a reference treatment~~.~~;

~~31. The method of any one of claims 1 to 30, wherein the method results in~~ (c) a lowered incidence of infection in the patient by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, at least 95%, or 100% relative to a reference treatment~~.~~;

~~32. The method of any one of claims 1 to 31, wherein the method results~~ (d) a faster induction of remission in the patient by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, at least 95%, or 100% relative to a reference treatment~~.~~; and/or

~~33. The method of any one of claims 1 to 32, wherein the method results~~ (e) a longer maintenance of remission in the patient by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, at least 95%, or 100% relative to a reference treatment.

~~34~~19. The ~~method of any one of~~ use according to claim~~s 29 to 33~~18, wherein the reference treatment is treatment with steroids (e.g. glucocorticoids), cyclophosphamide, an anti-CD20 monoclonal antibody (e.g. rituximab), methotrexate, azathioprine, mycophenolate, mycophenolate mofetil, avacopan, anti-TNF agents (e.g. infliximab, adalimumab, golimumab, etanercept), anti-IL6R antibodies (e.g. tocilizumab, sarilumab), costimulatory blockade (e.g. abatacept), JAK inhibitors (e.g. tofacitinib, baricitinib) and/or belimumab, preferably wherein the reference treatment is treatment with steroids, cyclophosphamide or rituximab.

~~35~~20. The ~~method of~~ use according to any one of claims 1 to ~~34~~19, wherein the ~~method~~ treatment or management is used for the induction of remission~~.~~ or

~~36. The method of any one of claims 1 to 34, wherein the method is used for~~ the maintenance of remission.